Loading stock data…
Ionis Pharmaceuticals (IONS)
$56.55+0.68 (+1.22%)
Market ClosedLast close Jul 24
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ionis Pharmaceuticals, Inc. in the Healthcare sector is trading at $56.55 with a market capitalization of $12.0B. Wall Street consensus targets $92.00 (20 analysts), implying a +62.7% move over the next 12 months. The stock is currently 35% below its 52-week high of $86.74, remaining 25.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +62.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $246.09M↑ | $203.33M↑ | $156.72M↓ | $452.05M↑ | $131.61M |
| Gross Profit | $243.09M↑ | $195.37M↑ | $154.38M↓ | $447.90M↑ | $130.11M |
| Operating Income | -$117.48M↑ | -$214.47M↓ | -$160.17M↓ | $139.84M↑ | -$146.95M |
| Net Income | -$92.53M↑ | -$229.39M↓ | -$128.61M↓ | $123.55M↑ | -$146.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-66.54%
Volume
Today's trading volume
2.66M
Recent News
How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story
Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design. This setback removes a late-stage cardiovascular candidate from Ionis’ pipeline spotlight and shifts attention toward earlier-stage RNA-targeted programs such as ION337 for Dravet syndrome. We’ll now examine...
Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh?
Ionis Pharmaceuticals (IONS) is back in focus after mixed R&D news, with the high profile CARDIO-TTRansform trial for eplontersen missing its primary endpoint, while the new ASCEND study for Dravet syndrome candidate ION337 has begun dosing. See our latest analysis for Ionis Pharmaceuticals. The recent CARDIO-TTRansform setback appears to align with a sharp loss of momentum in Ionis Pharmaceuticals’ share price, which is down 28.83% over the past 30 days and 32.21% year to date, even as the...
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High
Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.